Article Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 2

Release Date: October 17, 2008
Expiration Date: October 17, 2009

Publication Overview

Authors

Alessandra Tedeschi, MD; Barbara Eichhorst, MD; Dale L. Bixby, MD, PhD; Marco Montillo, MD; Michael Hallek, MD; Sami N. Malek, MD

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest
  3. Study the educational activity.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.
  • CME credit will be granted for only 1 form of participation, either online or via the printed publication.
View the Activity
You will be asked to login
or create an account.

About the Illustration About the Illustration:

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable clinical course that is associated with diverse responses to standard therapies, disease progression, and survival. A molecular definition of the spectrum of CLL illnesses is becoming possible by using integrated genomic profiling platforms, with profound implications for prognostication and designing risk-adapted strategies. The clinical diversity of CLL was exemplified by the seminal work of Dr. Döhner and colleagues, who identified genetic lesions that have significant prognostic value in terms of overall survival, with deletion of chromosome 17p (del[17p]) and del(11q) lesions emerging as the predominant negative prognostic factors and normal karyotypes or del(13q14) lesions showing favorable prognosis. Further characterization of del(13q14) genomic lesions identified molecular subtypes that could be classified into type I and type II subgroups with either retinoblastoma gene retention or loss, respectively. This figure shows clustering of heat map displays of copy number estimates for all patients at the 13q14.3 locus in the study, with each column representing a patient, copy losses displayed in blue, and copy gains displayed in red. Based on breakpoint mapping for 13q14 type I deletions using genomic Southern blotting, gene locations and orientations are depicted (far right). In this issue of CLL: The Cutting Edge, Drs. Bixby and Malek review progress in the current understanding of the genomic and molecular basis of CLL.

Ouillette P, et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008; 68:1012-21.

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. Bayer HealthCare Pharmaceuticals